Kairos Pharma Sets Virtual Annual Meeting, Discloses Going Concern Notice
Kairos Pharma announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncertainties for the clinical-stage biopharmaceutical company.
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. The company stated that meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission.
In a separate disclosure, Kairos Pharma revealed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm. The disclosure, made as required under Section 610(b) of the NYSE American Company Guide, does not reflect any change or amendment to previously filed financial statements. A going concern notice indicates that there is substantial doubt about the company's ability to continue as a going concern for the next 12 months, which is a significant red flag for investors.
This announcement underscores the financial challenges facing Kairos Pharma as it advances its lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. However, as of the date of the press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator.
The going concern notice is a critical development for Kairos Pharma, as it may affect the company's ability to secure additional financing, partnerships, or investor confidence. For a company still in the clinical stage with no approved products, such a disclosure can hamper efforts to raise capital necessary to continue operations and fund clinical trials. Investors should closely monitor the company's progress and any subsequent actions to address its financial condition.
For more details, the full press release is available at https://ibn.fm/sQ0pm. Latest news and updates relating to KAPA can be found in the company’s newsroom at https://ibn.fm/KAPA.